Vanda inks $11.5M deal to settle off-label drug promotion accusations

Nicole DeFeudis

Editor

Vanda Pharmaceuticals took the FDA to court three separate times this year as it struggles to win over regulators with its sleep and chronic digestive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vanda inks $11.5M deal to settle off-label drug promotion accusations

Nicole DeFeudis

Editor

Sign up to read this article for free.

Eli Lilly misses 2024 revenue expectations, stock dips 7%

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Can the Pfizer machine fight back against an activist investor?

HHS inspector general raises concerns over three FDA accelerated approvals

Charles River disappoints investors with damp outlook for 2025

Lykos upheaval continues with four new board exits amid hunt for cash

Van­da inks $11.5M deal to set­tle off-la­bel drug pro­mo­tion ac­cu­sa­tions

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Can the Pfiz­er ma­chine fight back against an ac­tivist in­vestor?

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

Charles Riv­er dis­ap­points in­vestors with damp out­look for 2025

Lykos up­heaval con­tin­ues with four new board ex­its amid hunt for cash

Vanda inks $11.5M deal to settle off-label drug promotion accusations

Eli Lilly misses 2024 revenue expectations, stock dips 7%

Can the Pfizer machine fight back against an activist investor?

HHS inspector general raises concerns over three FDA accelerated approvals

Charles River disappoints investors with damp outlook for 2025

Lykos upheaval continues with four new board exits amid hunt for cash